Helicobacter pylori and the Role of Lipopolysaccharide Variation in Innate Immune Evasion

Daniel Sijmons 1, Andrew J. Guy 1,2, Anna K. Walduck 1 and Paul A. Ramsland 1,3,4*

1 School of Science, RMIT University, Melbourne, VIC, Australia, 2 ZiP Diagnostics, Collingwood, VIC, Australia, 3 Department of Immunology, Monash University, Melbourne, VIC, Australia, 4 Department of Surgery, Austin Health, University of Melbourne, Heidelberg, VIC, Australia

Helicobacter pylori is an important human pathogen that infects half the human population and can lead to significant clinical outcomes such as acute and chronic gastritis, duodenal ulcer, and gastric adenocarcinoma. To establish infection, H. pylori employs several mechanisms to overcome the innate and adaptive immune systems. H. pylori can modulate interleukin (IL) secretion and innate immune cell function by the action of several virulence factors such as VacA, CagA and the type IV secretion system. Additionally, H. pylori can modulate local dendritic cells (DC) negatively impacting the function of these cells, reducing the secretion of immune signaling molecules, and influencing the differentiation of CD4+ T helper cells causing a bias to Th1 type cells. Furthermore, the lipopolysaccharide (LPS) of H. pylori displays a high degree of phase variation and contains human blood group carbohydrate determinants such as the Lewis system antigens, which are proposed to be involved in molecular mimicry of the host. Lastly, the H. pylori group of outer membrane proteins such as BabA play an important role in attachment and interaction with host Lewis and other carbohydrate antigens. This review examines the various mechanisms that H. pylori utilises to evade the innate immune system as well as discussing how the structure of the H. pylori LPS plays a role in immune evasion.

Keywords: H. pylori, innate immunity, lipopolysaccharide, dendritic cells, Lewis system antigens, molecular mimicry, adhesion, inflammation

INTRODUCTION

Helicobacter pylori is a gram-negative, spiral shaped bacterium that infects the stomach of up to half the world’s population. The prevalence is dependent on country and can vary between 20% to 80% (1). H. pylori also has a high rate of clinically asymptomatic infection, with some studies reporting a prevalence as high as 67% in entirely asymptomatic populations (2, 3). However, chronic infection with H. pylori can result in severe clinical conditions, and colonisation induces chronic inflammation in all infected individuals (4). These conditions are thought to be caused by damage to the gastric epithelium and prolonged inflammation associated with chronic infection and immune action (3).
Antibiotics are the mainstay of treatment for confirmed infections, and quadruple antibiotic therapy is currently recommended (5). H. pylori strains are however increasingly found to be resistant and treatment failure is not uncommon (6). The outcome of H. pylori infection is strongly influenced by both the bacterial genotype as well as host polymorphisms and is driven by an array of virulence factors possessed by H. pylori (7). Approximately 15% of cases result in symptomatic gastric disease including acute gastritis, chronic gastritis, and peptic ulcer (8). Furthermore, 1-2% of infections result in malignant neoplastic diseases such as mucosal-associated lymphoid tissue (MALT) lymphoma and gastric adenocarcinoma (8). As a result of this H. pylori is classified as a type one carcinogen by the World Health Organisation (WHO) (9). The severity of H. pylori disease, and the increasing incidence of antibiotic resistance means there is an urgent need for new therapies and vaccines.

H. pylori employs several mechanisms to evade innate immunity allowing the bacterium to establish chronic infection. Firstly, H. pylori occupies a unique infective niche in the hostile conditions of the human stomach, using the secretion of the enzyme urease to survive the natural barrier of the stomach’s acidity, coupled with the motility via its unipolar flagella (10). The motility of H. pylori allows it to maintain position and reside in the gastric mucous gel layer where it triggers inflammation. The net effect of H. pylori-induced inflammation is damage to the epithelial barrier, which presumably releases nutrients to promote bacterial growth.

Despite chronic infection, inflammatory responses to H. pylori infection remain relatively controlled in most cases due to a series of mechanisms that manipulate the host response, promoting persistent infection. H. pylori is able to adhere to mucins such as MUC5AC (11), as well as interacting with Lewis system antigens expressed on gastric epithelial cells (12), this allows it to maintain its position in the mucus gel layer and crypt isthmus and prevent its removal by the stomachs churning movement (10). Secondly, H. pylori can interact with and manipulate interleukin (IL) secretion of local dendritic cells (DC), negatively regulating the functions of these cells and suppressing cytokine release (13), influencing the differentiation of CD4+ T helper cells towards Th1 type cells (14). Finally, the lipopolysaccharide (LPS) of H. pylori displays a high degree of phase variation and contains human blood group carbohydrate determinants such as the Lewis system antigens (15-17). This review examines the various mechanisms H. pylori utilises to evade the innate immune system as well as discussing how the structure of the H. pylori LPS plays a prominent role in immune evasion.

OVERVIEW OF INNATE IMMUNITY IN THE CONTEXT OF BACTERIAL INFECTION

The innate immune system is the first line of defence against the many potential pathogens humans are exposed to daily (18). Epithelial surfaces and mucous membranes provide a physical barrier between internal organs and the external environment (19). The innate immune system also employs various antimicrobial peptides within the mucosal layer which have the ability to kill or inhibit microorganisms and viruses in the area (20). These initial defences are supported by more complex innate immune mechanisms. For example, pathogen-associated molecular patterns (PAMP) can be discerned from host molecular patterns by innate and adaptive immune cells allowing the triggering of a more extensive immune response (21). PAMP frequently include molecules such as glycans and glycoconjugates which may be expressed in structures like the LPS of a gram-negative bacterium (22). Detection of these structures are commonly associated with two classes of proteins known as toll-like receptors (TLR) and nucleotide-binding oligomerization domain-like receptors (NLR), as well as complement components circulating in the blood (23). The TLR expressed in humans are particularly well characterised, with TLR2, TLR4 and TLR5 commonly associated with the detection of lipopolysaccharide structures such as a bacterial LPS or flagella, whereas TLR3, TLR7, TLR8 and TLR9 are associated with the detection of foreign nucleic acids (24). Nod-Like Receptors recognise components of the bacterial cell wall, their activation triggers the release of pro-inflammatory cytokines and have synergistic effects with TLR in immune system signaling pathways (25).

Pathogen recognition triggers several supporting immune functions such as the activation of proinflammatory effector molecules. Inflammation is an important part of the immune response and inflammasomes are a system of innate immune receptors that activate the cystine protease caspase-1 and induce inflammation in response to the presence of infectious microbes (26). Additionally, inflammasomes contribute to the activation of proinflammatory cytokines IL-1β and IL-18, which induce an influx of innate immune cells into a potentially infected area, resulting in the engulfment of the bacterium by phagocytes including macrophages and monocytes. Engulfed bacteria are encased in an intracellular vesicle, the phagosome, where the phagocytic cells concentrate molecules which are deadly to bacterial cells, including antimicrobial substances, reactive oxygen species and reactive nitrogen intermediates. As well as immediate destruction, the engulfment, or phagocytosis of bacteria can also function as a form of antigen presentation for the activation of the adaptive immune system (29). A specialised type of phagocyte known as the dendritic cell (DC) plays a primary role in the activation of the adaptive immune system. Once a DC engulfs a bacterium, it processes the bacterial cell and presents its antigens in complex with major histocompatibility molecules (MHC) to lymphocytes to induce T cell and B cell maturation and differentiation, triggering the adaptive immune response (30).

IMMUNE RESPONSE AGAINST H. PYLORI

Various innate immune mechanisms are activated by the colonisation of H. pylori. Toll-like receptors (TLR) 2, 4 and 5 can recognise PAMP of H. pylori (31), triggering immune pathways that activate NF-kB and IL-8 inducing a local proinflammatory response (32). H. pylori are extracellular and
generally non-invasive, but secretion of urease and the VacA toxin trigger local inflammatory responses. The most researched virulence factor is the type IV secretion system (TIVSS) encoded by the Cag pathogenicity island carried by type I strains (33). After bacterial adherence the TIVSS delivers the cytotxin CagA to the cytoplasm where it initiates intracellular signaling cascades that activate NF-kB (34), contributing to the local inflammatory response. The combined effect of this inflammation results in erosion of the epithelium, releasing nutrients for the bacteria to grow and colonise (35). Furthermore, intracellular pathogen recognising molecules such as NOD1 can bind H. pylori peptidoglycans that are introduced into epithelial cells via the TIVSS and trigger the release of other anti-microbial proteins in response, restricting bacterial growth and initiating additional immune action (36). While additional macrophages may be stimulated, H. pylori is able to neutralise macrophage nitric oxide production reducing the immune action of the cell (37). Once H. pylori has overcome the initial epithelial response, persistent infection drives an adaptive immune response triggered by dendritic cells. The local response consists of humoral and T cell (particularly Th1 and Th17) activation. Overall there is an influx of plasma cells, lymphocytes, neutrophils and other immune cells into the gastric mucosa during H. pylori infection, however this rarely results in complete clearance of the bacterium, and over time a significant population of regulatory T cells become established (38). This control of inflammation by H. pylori probably explains why many H. pylori infected individuals remain asymptomatic.

The stomach has relatively few polymeric immunoglobulin receptors (plgR), the receptor responsible for IgA transportation, in comparison to the rest of the gastrointestinal tract (39). This is altered in chronic H. pylori infection with upregulation of the plgR caused by raised γ-interferon levels associated with prolonged inflammation (40). Upregulation of plgR does not result in a corresponding increase in local secretory IgA levels, with monomeric non-secretory IgA predominating in the stomach of those infected with H. pylori (41). In contrast, secretory IgA is commonly observed in response to intestinal commensals and pathogens, suggesting a different mode of action of plgR in the stomach. Systemic H. pylori specific IgG is also produced in adults experiencing chronic infection (42).

### Role of H. pylori Virulence Factors in Induction of Innate Immune Responses and Immune Evasion

The natural immune response against H. pylori does not effectively clear infection and a combination of immune evasion techniques and bacterial factors leads to a persistent infection (Figure 1 and Table 1). Initial Type 1 inflammatory responses in most infected persons become biased over time towards Th2 and Treg that acts in a kind of damage control measure, which does not clear infection but reduces damage to the host (59–61).

An important feature of H. pylori is its ability to overcome natural barriers preventing most microbes from colonising the human stomach (62, 63). Early studies concluded that H. pylori flagellin evades TLR5 recognition and recombinant H. pylori flagellin was considerably less stimulatory than Salmonella flagellin for example (64). Furthermore, a series of residues within the CD0 domain of H. pylori flagella protein FlA has recently been found to enable evasion of TLR5 (Figure 1), these are speculated to be a result of point mutations not present in flagella proteins from other bacterium (65). However, a number of studies have now reported that H. pylori activates both TLR2 and 5 on epithelial cells, but not TLR4 (66). A recent report revealed that TLR5 activation is via interaction with the CagY protein which forms part of the TIVSS (67).

CagA is one of the most studied and most important virulence factors possessed by H. pylori. Contact and adherence of H. pylori to host gastric epithelial cells upregulates the expression of both CagA and VacA, as well as inducing the synthesis and assembly of the TIVSS (Figure 2) (71). Both CagA and the TIVSS are encoded by the cag PAI which is an approximately 40 kb chromosomal DNA region present in the most virulent strains of H. pylori. The TIVSS is a pilus-based “molecular syringe” structure that translocates CagA protein into host epithelial cells. The Type IV pilus binds epithelial cells via interaction with β1 integrin on the basolateral side (72). The bacteria gain access to the basolateral side through secretion of the HtrA enzyme which breaks down tight junctions (33).

Once in the cytoplasm, translocated CagA associates with Src and c-Abl family kinases which phosphorylate the CagA carboxyl-terminal EPIYA motif in the inner host cell membrane. Phosphorylated CagA then interferes with host cell signaling pathways, disrupting cell-cell junctions (73). In addition, CagA targets and causes the ubiquitination of the upstream kinase TAK1 (74). The downstream effects of CagA induce signaling cascades that activate NF-kB and downstream proinflammatory signaling (IL-8 secretion), cytoskeletal rearrangements, and changes to tight junctions (31, 33, 75) and inducing apoptosis (70, 76). Higher levels of CagA were shown to cause nuclear translocation of the AP-1 transcription factor and nuclear factor of activated T-cells (NFAT) (77). Furthermore, CagA is directly related to H. pylori carcinogenesis, enhancing DNA double strand breaks, and disabling homologous recombination-mediated DNA repair as well as stimulating Hippo signaling via the inhibition of PARI-mediated BRCA1 phosphorylation (78). Additionally, recent work has indicated that CagA initiates the oncogenic YAP pathway, further contributing to the association between CagA and gastric cancer risk (79, 80).

Infection with CagA positive H. pylori strains is one of the strongest risk factors for the development of gastric cancer (75). In addition, multiple H. pylori outer membrane proteins are associated with proinflammatory cytokine induction (Figure 2), these include OipA and BabA, which can induce IL-6, IL-8 and IL-11 (44, 45, 81). Like many bacteria, H. pylori have also been shown to release outer membrane vesicles (OMV) which contain various components, notably including portions of the H. pylori LPS as well as Hop family proteins including BabA and SabA along with other major virulence factors such as VacA and CagA.
Interestingly, it appears that *H. pylori* is also able to regulate cytokine release from host epithelial cells via small noncoding RNAs that have been detected in OMV. These OMV have been shown to suppress IL-8 stimulation from AGS cells in cell culture, presumably by targeting host cell mRNAs, effectively reducing the overall immunostimulatory response to *H. pylori* LPS and outer membrane proteins (83). Consequently, OMV may play a role in immune modulation and disease progression. Regulation of cytokine release by *H. pylori* has also been investigated in relation to inflammasomes. *H. pylori* can modulate NLRP3, a regulator important for inflammasome activation, by inducing secretion of IL-10 in THP-1 monocytic leukemia cell lines, and through the action of miRNAs such as has-miR-223-3p (84). Furthermore, *H. pylori* infection was reported to suppress the secretion of mature IL-1β from human THP1 monocytes, in spite of upregulation of pro-IL-1β, potentially promoting bacterial persistence (85). Interestingly, cytokine expression has been seen to differ between children and adults, with IL-1β, IL17A, IL-23, IL2, IL-12p70 and IFN-γ upregulated in adults and downregulated in children, and IL-6,
TGF-β1, IL-10, TNF-α and IL-1a downregulated in adults and upregulated in children. As a result of these differences, children display a Treg primary response as opposed to the Th1 and Th17 response seen in adults (86–88). The virulence factor HP-NAP also plays a major role in inducing and modulating host inflammation, recruiting neutrophils to the site of infection and causing a large increase in the neutrophil secretion of reactive nitrogen species, as well as stimulating the release of IL-12 and IL-23 from both neutrophils and monocytes (89). In vitro studies using cloned CD4⁺ T cells from allergen induced T cell lines have shown HP-NAP acts as a Th2 agonist, redirecting Th2 responses into Th1 to drive further inflammation through cytotoxic Th1 responses characterised by increased TNF-α and interferon-γ (Figure 2) (56).

*H. pylori* is able to adhere to both the secreted gastric mucin MUC5AC (90) and gastric epithelial cells via several surface proteins, such as the blood group binding adhesin (BabA) and the sialic acid binding adhesin (SabA). These surface proteins interact with carbohydrate determinants such as the host Lewis system antigens, again providing a mechanism by which *H. pylori* prevents its removal by peristalsis as well as gastric shedding (Figure 2) (46).

*H. pylori* also expresses Lewis system antigens within the LPS, that is thought to represent a form of molecular mimicry which subverts the host immune response. Indeed, there is also evidence suggesting the expression of Lewis determinants is involved in *H. pylori* interacting with the DC calcium dependent (C-type) lectin DC-SIGN (Table 1) (91). Upon phagocytosis by an innate immune cell, *H. pylori* can also avoid destruction by interfering with phagosome maturation (Figure 2) (92). Another method of immune evasion used by *H. pylori* involves the interaction with DC (Figure 1). While *H. pylori* inhabits a unique niche in the stomach where few cells have access, there has been strong evidence of DC interaction, with DC maturation and function heavily affected in mouse models (93). Furthermore, there is evidence of *H. pylori* having the capability to infect DC in cell culture (48). *H. pylori* is capable of modulating IL-12 secretion by DC affecting the maturation and differentiation of CD4⁺ T cells and causing Th1 bias in mice (94). In-vitro studies have supported this, with *H. pylori* demonstrating the ability to modulate expression of IL-12 and TNF-α in cultured DC (95).

In addition to manipulating DC responses, other virulence factors including VacA (96) along with γ-glutamyltranspeptidase...
(GGT) (97) and CagA (98) have been reported to interfere with the T cell response to *H. pylori*, causing a characteristic hyposensitivity of CD4+ T cells and suppressing mucosal effector T cells (99). Notably, VacA has been found to have an influence on both DC cytokine expression and T cell differentiation, with VacA positive *H. pylori* strains showing the ability to suppress IL-23 secretion by DC resulting in increased proliferation of Th17 cells. VacA plays additional roles in immune mediation including showing the ability to impair lysosomes and autophagosomes, a function with which VacA shares a synergistic effect with CagA, impairing the ability of both macrophages and gastric epithelial cells to remove internalised or invading bacteria. Specifically, *H. pylori* is able to inhibit the functions of lysosomal enzymes acid phosphatase, N-acetyl-β-d-glucosaminidase, and cathepsin D, prevent autolysosomal acidification, interfere with retrograde trafficking of mannose-6-phosphate receptors and inhibit autophagosome formation to promote intracellular survival of the bacterium (100).

It is likely *H. pylori* is highly resistant to destruction by phagocytes, although this has only been seen *in vitro* (101). Even though *H. pylori* is frequently engulfed by phagocytes in *vitro*, it is proficient at neutralising and resisting the reactive oxygen and nitrate species released by monocytes and macrophages. This allows the bacteria to continue to replicate inside the phagosome, eventually inducing apoptosis of the host cell (49, 101). *H. pylori* possessing the cag pathogenicity island (cagPI) are even more resistant to phagocytosis than other strains (102), with isogenic mutants of *H. pylori* lacking cagPI far more readily taken up by phagocytes (49). The mechanism for this appears to be the ability of *H. pylori* to activate the reverse transsulfuration pathway to induce cystathionine γ-lyase (CTH) in host macrophages, promoting bacterial growth and enhancing bacterial survival in macrophages. *H. pylori* does this via the CagA-dependent induction of the PI3K/AKT1 pathway, the CagA-independent induction of the MTOR pathway and activation of SPI, increasing macrophage production of CTH (103). Furthermore, it has been shown that *H. pylori* is able to upregulate the metabolism of macrophage-associated polyamines, impairing M1 macrophage function (104).

### Antibody Activity and Humoral Immune Evasion by *H. pylori*

The mechanisms of humoral immune evasion by *H. pylori* are somewhat less clear. Most immunocompetent individuals who are infected with *H. pylori* develop a specific IgG and IgA response, in many cases high antibody titres to the pathogen, however, this often is not enough to clear infection (53, 105). Furthermore, it has been reported that the type of antibody produced correlates with the outcome of infection, with patients experiencing gastritis and duodenal ulcers having greater titres of IgG, and patients suffering from gastric cancers often having greater titres of IgA (106). Other studies have suggested that a weaker overall antibody response is linked to the development of gastric cancers, and patients who had a weak but still detectable antibody response to *H. pylori* had a higher rate of gastric cancer than those with a stronger antibody response (107–109).

### H. pylori LPS and Lewis Antigens

*H. pylori* both interacts with host Lewis system antigens and displays Lewis antigens in its LPS. The expression of Lewis antigens by *H. pylori* is associated with immune evasion and a reduced immunogenicity of its LPS when compared to other bacteria (110, 111). The reduced immunogenicity of *H. pylori* LPS is related to its structure, much like that of other gram-negative bacterium, the *H. pylori* LPS contains 3 domains: a hydrophobic lipid A domain on the outer bacterial membrane, a core oligosaccharide and a repetitive oligosaccharide termed the O chain (111). The O chain of the *H. pylori* LPS is the main location where Lewis system antigens are displayed by the organism (112). The *H. pylori* O antigen is typically composed of a Gal-GlcNAc backbone chain which is divided into two types based on its linkage (Figure 3). Type 1 chains are composed of Galβ1-3GlcNAc, which forms the core saccharide for Lea, sialyl-Lea and Leb. Type 2 chains are composed of Galβ1-4GlcNAc or LacNAc, which forms the core saccharide for Lea, sialyl-Lea and Leβ (63). In humans, Lewis system antigens like ABO blood group antigens are expressed in fluids and tissue including the gastric mucosa and endothelium. Lea and Leβ are commonly expressed on various cell types from red blood cells to gastric epithelial cells, with Leβ in particular associated with various pathologies (113). In the human stomach, Lea and Leβ are predominantly expressed on the surface and foveolar epithelia, whereas Leβ and Lea are predominantly expressed in the mucus as well as the chief and parietal cells of the gastric glands. More specifically, non-secretory cells in the surface and foveolar epithelia express Lea while Leβ and Leβ are expressed in secretory cells (114). Clinical isolates of *H. pylori* typically have a poly-LacNAc with several α-L-fucose residues forming internal Lea determinants with terminal Leβ and Leβ determinants, while other strains have been described as displaying Lea, Leβ and sialyl-Leβ as well as group A, B and H-1 determinants (111). As many as 90% of clinical isolates of *H. pylori* contain Lewis antigens in the O antigen portion of the LPS. This expression has been found to be relatively stable after subculturing using methods such as immunoblot. However, it is possible for cultured *H. pylori* strains to lose Lewis antigen expression over time (68, 115).

### H. pylori LPS Structure, Phase Variation, and Diversity

As described above, the O antigen portion of the *H. pylori* LPS is associated with the expression of various Lewis antigens in addition to playing a role in the adhesion and immune evasion of the bacterium (116). The O antigen chain is comprised of a glucan group (saccharide composed of glucose), a D-glycerol-D-manno-heptan (DD-heptan) group and a highly conserved trisaccharide (trio) (115). Variability in the O antigen is derived from phase variation, whereby *H. pylori* uses an on/off system to regulate its biosynthetic genes, including the fucosyltransferase genes FutA, FutB, and FutC (117), allowing the bacterium to adjust the carbohydrate expression of the O
antigen with the changing environment of the stomach and gastric mucosa (16). Additionally, phase variation of the \textit{H. pylori} LPS allows for a greater range of phenotypes and gives \textit{H. pylori} the ability to modify the expression of Lewis system antigens in its LPS. Additionally, it has been indicated that the \textit{H. pylori} LPS induces lower biological responses when compared to other gram-negative organisms such as \textit{E. coli} and \textit{Salmonella} spp., with \textit{in vivo} mouse and rabbit studies showing 500 to 1000 fold lower mitogenic and pyrogenic responses (118).

The genes encoding the glycotransferases responsible for the construction of this LPS vary between different regional strains, with the common European strain of \textit{H. pylori} G27 possessing the trisaccharide fucosyltransferase (HP0102), heptan transferase (HP1283) and GlcNAc transferase (HP1578), the last of which is responsible for initiating synthesis of Lewis system antigens onto a heptan motif (111). In addition to this, a comparison between the European model strain G27 and East Asian strains found that the East Asian strains lacked the genes encoding for heptan transferase and GlcNAc transferase (119). Furthermore, East Asian strains instead express additional copies of other genes, HP1105 and JHP0562, which may act as GlcNAc transferases as well as Gal transferase in place of HP1578 (119). This was identified as an area of interest due to the higher rates of gastric cancer in East Asia and the potential to further characterise the role of the \textit{H. pylori} LPS heptan in pathogenesis (119). Figure 3 illustrates an abbreviated version of the established structure of the O antigen structure from the mouse-adapted \textit{H. pylori} SS1 strain including the trio, attachment site and the Lewis antigenic determinants.

\textbf{\textit{H. pylori} LPS Structural Diversity in Infection and Immune Evasion}

The \textit{H. pylori} LPS is generally considered less immunogenic in comparison to enterobacterial LPS, with early studies showing significant reductions in pyrogenicity, mitogenicity and toxicity, as well as a reduced cytokine and chemokine response (118, 120, 121). Previous studies have shown that synthesised partial \textit{H. pylori} LPS structures, specifically lipid A compounds and Kdo-lipid A compounds, can modulate cytokine production by host cells. All lipid A and Kdo-lipid A \textit{H. pylori} LPS structures synthesised either failed to induce, or induced very low levels of IL-1\textbeta, IL-6 and IL-8, and conversely stimulated high levels of cytokines IL-12 and IL-18 in heparinised human peripheral whole blood (122, 123). IL-12 induction by \textit{H. pylori} is generally linked to MyD88 expression in macrophages (124). Furthermore, \textit{H. pylori} modifies the lipid A portion of the LPS by via dephosphorylation of the 1- and 4-’positions of the lipid A backbone. Mutations to the lpxE/F machinery required for this modification have shown an increased susceptibility of \textit{H. pylori} to the antimicrobial peptide polymyxin B, as well as reducing the ability of \textit{H. pylori} to colonise mice (125). Knockout studies on \textit{H. pylori} genes HP0044 and HP1275 demonstrated the production of a truncated \textit{H. pylori} LPS missing fucose residues found in both the trio and Lewis antigen portions of the \textit{H. pylori} LPS O antigen, resulting in the loss of a significant portion of the \textit{H. pylori} LPS. This in turn affected the growth of the bacterium, increased its susceptibility to both the detergent SDS, promoted bacterial autoaggregation, increased surface hydrophobicity and affected bacterial virulence and OMV protein sorting (126). Notably, phase variation of \textit{H. pylori}
fucosyltransferases, and consequently the glycosylation pattern of the LPS has previously been identified to occur in high frequencies, with in-vitro studies demonstrating the expression of Le^e_ can vary at a frequency of 0.2-0.5% resulting in differing LPS variants in the same population. Variation of Lewis antigen expression, particularly between Le^a_ and Le^b_ has been suggested to be influenced by relative pH in liquid medium. The function for this has not been fully identified, but is hypothesised to aid in bacterial persistence (127). On a molecular level the variation in H. pylori fucosylation has previously been attributed to slipped-strand mispairing as a result of differing numbers of polyC repeats in fucosyltransferase genes _futA_, _futB_ and _futC_. However, a recent study has described a role for small RNAs (sRNA) in the regulation of the H. pylori LPS biosynthesis. The sRNA RepG modulate _HP0102_ and _TlpB_, providing post-transcriptional regulation to LPS biosynthesis potentially indicating further means by which _H. pylori_ is able to adapt to host immune response (128).

**ROLE OF _H. PYLORI_ ADHESINS IN IMMUNE EVASION**

In addition to _H. pylori_ commonly expressing Lewis determinants in its LPS, _H. pylori_ also binds to host Lewis determinants, assisting in the attachment of the bacterium to the gastric epithelium (129, 130). Binding is facilitated by a group of outer membrane proteins, including BabA and SabA.

**BabA**

_H. pylori_ binds to the various Lewis system antigens expressed on the surface of gastric epithelial cells, including Le^b_ and sialyl-Le^a_ (131). Chronic inflammation also leads to upregulation of Le^e_ and Le^b_ in the host, further enhancing bacterial colonisation (131). Furthermore, _H. pylori_ has a range of adhesive proteins that have been identified and examined. The first identified was BabA, a protein that commonly binds the Le^b_ determinant as well as mucin proteins and the H1 blood group antigen (132). Specifically, BabA binds the lacto series of glycans containing a terminal fucose molecule with an α1,2 linkage attached to a Galβ1-3GlcNAc core (133). This includes H1 blood group antigen as well as other H neoglycoconjugates and Le^b_. However, BabA binds to Le^b_ with as much as a two-fold increase in affinity in comparison to H neoglycoconjugates and Le^b_. The BabA encoding gene(s) can be found in three separate loci on the _H. pylori_ genome with the binding pattern of the protein differing based on the specific loci expressed (135). For example, strains containing locus A BabA (BabA2) bind the classically associated Le^b_ whereas strains with locus B BabA (BabA1) do not bind to Le^b_ (136). Furthermore, some strains may contain more than one BabA encoding gene allowing expression of proteins with varying binding characteristics (137). BabA in general is a highly polymorphic protein with variable expression, which may be lost during laboratory cultivation. Additionally about one quarter of strains isolated from chronically infected hosts tend to lose BabA expression (69, 138). This suggests that BabA is a specific adhesin that is advantageous in the colonisation of a human host that is unnecessary on solid media (137). There has been evidence of numerous binding molecules for BabA in addition to the Le^b_ molecules expressed by gastric epithelia. Several salivary proteins have also been identified to interact with BabA, such as the mucin MUC5B, the agglutinin glycoprotein-340 and the proline-rich glycoprotein containing the Fucct1-2Galβ motif. In addition to this, fucose-containing oligosaccharides present in secretory IgA also play a role in binding BabA, however this is not universal to all secretory IgA (132). It has been observed that BabA presence in a _H. pylori_ strain is associated with expression of VacA, CagA and OipA among other common but variable virulence factors, particularly in the outcome of gastric metaplasia. An in-vitro study found that Le^b_-positive AGS cells expressed increased levels of mRNA for the cytokines CCL5 and IL-8 as well as precancer related factors CDX2 and MUC2 in the presence of wild type _H. pylori_, however this was not the case for _H. pylori_ mutants with either BabA genes or TIVSS deleted (139).

**SabA**

SabA is an additional adhesion molecule associated with the binding of _H. pylori_ system determinants by _H. pylori_. More specifically, SabA binds sialylated molecules such as sialyl-Le^a_ and some gangliosides characterised by Neu5Acα2-3-neolactohe-axosylceramide and Neu5Acα2-3-neolactooctasylceramide molecules (58). The gastric inflammation caused by _H. pylori_ infection is essential for changes in glycosylation patterns within the gastric mucosa, promoting the expression of sialyl-Le^a_ as well as sialyl-Le^b_, which in turn increases the adhesive properties of SabA (140). Similar to BabA, the expression of SabA is highly variable and is often subject to phase variation. It has been suggested that _H. pylori_ may have multiple means of modulating the expression of SabA, with one such method being an acid-responsive ArsRS two-component signal transduction system, and an alternative involving the slipped-strand mispairing of SabA alleles during chromosomal replication in various _H. pylori_ subpopulations (141). Additionally, SabA is commonly subject to homologous recombination and gene conversion due to changing environmental pressures (142). Deactivation of the SabA encoding gene may further assist in bacterial escape as cytotoxic activity by neutrophils is in part triggered by SabA binding to gangliosides. Neutrophil action has been shown to be defective against SabA deleted _H. pylori_ cells (58).

**OipA**

OipA is also a member of the Hop family of outer membrane proteins possessed by _H. pylori_. There is currently no available crystal structure for OipA, limiting detailed studies of its binding (143). OipA is known to be closely associated with the _cag_ PAI and CagA, with the _oipA_ locus approximately 100 kb from the _cag_ PAI. OipA is regulated by slipped-strand mispairing and displays on/off states which are closely associated with the expression of CagA. Alleles of _oipA_ have been demonstrated in up to 96% of _cag_ PAI positive _H. pylori_ strains, solidifying the relationship of the two virulence factors (144). With the exception of CagA, OipA is typically independent of other _H. pylori_ virulence factors. OipA is associated with the induction of
IL-8 from host epithelial cells, inhibition of apoptosis and enhanced adhesion to gastric cells in vitro (143). Induction of IL-8 and its subsequent role in inducing gastritis has been associated with a synergistic effect from H. pylori strains possessing both the cag PAI and a functional oipA gene (145). In contrast oipA “off” strains can down-regulate anti-apoptotic processes in AGS cells, more regularly inducing apoptosis on infection than oipA “on” strains in-vitro (146).

CONCLUSIONS

H. pylori is a very successful global pathogen and has adopted a range of adaptions to evade the innate immune system. These mechanisms include both active systems, such as the neutralisation of reactive oxygen and nitrogen species released by macrophages, the modulation of cytokine secretion and the maturation of dendritic cells, and more passive systems such as the variability and the uniquely low immunogenicity of its LPS (15, 53). In addition, the expression of Lewis antigens in the LPS of H. pylori gives the bacterium the ability to mimic host antigens and thereby hide from the immune system (147). Notably, several of the immune evasion mechanisms H. pylori employs are yet to be fully explained. For example, knowledge of H. pylori activation and modulation of innate immunity outside of interactions with dendritic cells and DC-SIGN is surprisingly limited. It is also known that outer membrane proteins such as BabA, SabA and OipA play a role in the induction of inflammatory cytokines, although the molecular mechanism is still unclear (44, 144). Further study into ways to circumvent the methods H. pylori uses for immune evasion could allow for improved treatment and vaccination options. Additionally, blocking the activity of H. pylori adhesins to prevent attachment in the gastric mucosal gel layer and to epithelial cells has potential for new treatment options in an environment of increased antibiotic resistance.

AUTHOR CONTRIBUTIONS

DS, prepared figures and wrote the manuscript; AG, critically reviewed and commented on the manuscript; AW, critically reviewed and commented on the manuscript; PR, critically reviewed and commented on the manuscript. All authors conceived and discussed the topic of the review. All authors read and approved the final manuscript.

FUNDING

DS is supported by a Research Training Program Stipend Scholarship from the Australian Government, Department of Education and Training.

REFERENCES

1. Venerito M, Link A, Rokkas T, Malfertheiner P. Review: Gastric Cancer—Clinical Aspects. Helicobacter (2019) 24(S1):e12643. doi: 10.1111/hel.12643
2. Mungazi SG, Chihaka OB, Muguti GI. Prevalence of Helicobacter Pylori in Asymptomatic Patients at Surgical Outpatient Department: Harare Hospitals. Ann Med Surg (Lond) (2018) 35:153–7. doi: 10.1016/j.amsu.2018.09.040
3. Lim SH, Kwon J-W, Kim N, Kim GH, Kang JM, Park MJ, et al. Prevalence and Risk Factors of Helicobacter Pylori Infection in Korea: Nationwide Multicenter Study Over 13 Years. BMC Gastroenterol (2013) 13:104. doi: 10.1186/1471-230X-13-104
4. Dunne C, Dolan B, Clyne M. Factors That Mediate Colonization of the Human Stomach by Helicobacter Pylori. World J Gastroenterol (2014) 20(19):5610–24. doi: 10.3748/wjg.v20.i19.5610
5. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter Pylori Infection—the Maastricht V/Florence Consensus Report. Gut (2017) 66(1):6–30. doi: 10.1136/gutjnl-2016-312288
6. Tshibangu-Kabamba E, Yamaoka Y. Helicobacter Pylori Infection and Antibiotic Resistance - From Biology to Clinical Implications. Nat Rev Gastroenterol Hepatol (2021) 18(9):613–29. doi: 10.1038/s41575-021-00449-x
7. Rosczzenko-Jasinska P, Woitay MI, Jagusztyn-Krynicka EK. Helicobacter Pylori Treatment in the Post-Antibiotics Era-Searching for New Drug Targets. Appl Microbiol Biotechnol (2020) 104(23):9891–905. doi: 10.1007/s00253-020-10945-w
8. Testerman TL, Morris J. Beyond the Stomach: An Updated View of Helicobacter Pylori Pathogenesis, Diagnosis, and Treatment. World J Gastroenterol (2014) 20(36):12781–808. doi: 10.3748/wjg.v20.i36.12781
9. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin (2005) 55(2):74–108. doi: 10.3322/canjclin.55.2.74
10. Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter Pylori Infection. Clin Microbiol Rev (2006) 19(3):449–90. doi: 10.1128/CMR.00054-05
11. Van den Brink GR, Tytgat KM, van der Hulst RW, van der Loos CM, Eimerhand AW, Bülter HA, et al. H Pylori Colonisations With MUC5AC in the Human Stomach. Gut (2000) 46(5):601–7. doi: 10.1136/gut.46.5.601
12. Doohan D, Rezkitha YAA, Waskito LA, Yamaoka Y, Mfiahusumur M. Helicobacter Pylori BabA-SabA Key Roles in the Adherence Phase: The Synergic Mechanism for Successful Colonization and Disease Development. Toxins (Basel) (2021) 13(7):485. doi: 10.3390/toxins13070485
13. Tanaka H, Yoshida M, Nishiumi S, Ohnishi N, Kobayashi K, Yamamoto K, et al. The CagA Protein of Helicobacter Pylori Suppresses the Functions of Dendritic Cell in Mice. Arch Biochem Biophys (2010) 498(1):35–42. doi: 10.1016/j.abb.2010.03.021
14. Kim JM, Kim JS, Yoo DY, Ko SH, Kim N, Kim H, et al. Stimulation of Dendritic Cells With Helicobacter Pylori Vacculizing Cytoxinin Negatively Regulates Their Maturation via the Restoration of E2F1. Clin Exp Immunol (2011) 166(1):34–45. doi: 10.1111/j.1365-2249.2011.04447.x
15. Pece S, Giuliani G, Di Leo A, Fumara D, Antonaci S, Jirillo E. Role of Lipopolysaccharide and Related Cytokines in Helicobacter Pylori Infection. Recent Opt Med (1997) 88(5):237–41.
16. Appelmelk BJ, Martino MC, Veenhof E, Monteiro MA, Maaskant JJ, Negrini R, et al. Phase Variation in H Type I and Lewis a Epitopes of Helicobacter Pylori Lipopolysaccharide. Infect Immun (2000) 68(10):5928–32. doi: 10.1128/iai.68.10.5928-5932.2000
17. Perepelov AV, Szenchenkova SN, Knirel YA. Variations in the Expression of Variations in the Expression of Lewis Antigens in the Lipopolysaccharide of Helicobacter Pylori. Arch Biochem Biophys Dendritic Cell in Mice. Arch Biochem Biophys (2010) 498(1):35–42. doi: 10.1016/j.abb.2010.03.021
18. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Innate Immunity. In: Molecular Biology of the Cell. New York: Garland Science (2002).

Frontiers in Immunology | www.frontiersin.org 9 May 2022 | Volume 13 | Article 868225

Sijmons et al. Innate Immune Evasion by Helicobacter pylori
19. Muñoz-Carrillo JL, Rodríguez F, Gutierrez O, Moreno García M, Cordero J. Physiology and Pathology of Innate Immune Response Against Pathogens. In: Rexei N, editor. Physiology and Pathology of Immunology. London: IntechOpen (2017) p. 99–134. doi: 10.5772/intechopen.70585

20. Pasupuleti M, Schmidtschen A, Malmsten M. Antimicrobial Peptides: Key Components of the Innate Immune System. *Crit Rev Biotechnol* (2012) 32 (2):143–71. doi: 10.3109/07388551.2011.594423

21. Maverakis E, Kim K, Shimoda M, Gershwin ME, Patel F, Wilken R, et al. Glycans in the Immune System and The Altered Glycan Theory of Autoimmunity: A Critical Review. *J Autoimmun* (2015) 57:1–13. doi: 10.1016/j.jaut.2014.12.002

22. Akira S, Uematsu S, Takeuchi O. Pathogen Recognition and Innate Immunity. *Cell* (2006) 124(4):783–801. doi: 10.1016/j.cell.2006.02.015

23. Medzhitov R. Recognition of Microorganisms and Activation of the Immune Response. *Nature* (2007) 449(7164):819–26. doi: 10.1038/nature06246

24. Diacovich L, Gorvel J-P. Bacterial Manipulation of Innate Immunity to Promote Infection. *Nat Rev Immunol* (2010) 8(2):117–28. doi: 10.1038/nri2295

25. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-Like Proteins in Immunity, Inflammation and Disease. *Nat Immunol* (2006) 7(12):1250–7. doi: 10.1038/nri1412

26. Guo H, Callaway JB, Ting JPY. In *Cell Microbiol* (2017). p. 187–220.

27. Guo Y, Feinberg H, Conroy E, Mitchell DA, Alvarez R, Blixt O, et al. Helicobacter Pylori–Induced IL-1β Secretion in Innate Immune Cells Is Regulated by the NLRP3 Inflammasome and Requires the Cag Pathogenicity Island. *J Immunol* (2014) 193(7):3566–76. doi: 10.4049/jimmunol.1400362

28. Mitchell P, Germain C, Fiori PL, Khamri W, Foster GR, Ghosh S, et al. Chronic Exposure to Helicobacter Pylori Impairs Dendritic Cell Function and Inhibits Th1 Development. *Infect Immun* (2007) 75(2):810–9. doi: 10.1128/iai.00228-06

29. Ramarao N, Meyer TF. Helicobacter Pylori Resists Phagocytosis by Macrophages: Quantitative Assessment by Confocal Microscopy and Fluorescence-Activated Cell Sorting. *Infect Immun* (2001) 69(4):2604–11. doi: 10.1128/IAI.69.4.2604-2611.2001

30. Ottemann KM, Lowenthal AC. Helicobacter Pylori Uses Motility for Initial Colonization and to Attain Robust Infection. *Infect Immun* (2002) 70(4):1984–90. doi: 10.1128/iai.70.4.1984-1990.2002

31. Tsuda M, Karita M, Morshed MG, Okita K, Nakazawa T. A Urease-Negative Mutant of Helicobacter Pylori Constructed by Allelic Exchange Mutagenesis Lacks the Ability to Colonize the Nude Mouse Stomach. *Infect Immun* (1994) 62(8):3586–9. doi: 10.1128/IAI.62.8.3586-3589.1994

32. Fan X, Guasena H, Cheng Z, Espeso R, Cresoe SE, Ernst PB, et al. Helicobacter pylori Urease Binds to Class II MHC on Gastric Epithelial Cells and Induces Their Apoptosis. *J Immunol* (2000) 165(4):1918–24. doi: 10.4049/jimmunol.165.4.1918

33. Lina TT, Alzahrani S, Gonzalez J, Pinkuch IV, Beswick EI, Reyes VE. Immune Evasion Strategies Used by Helicobacter Pylori. *World J Gastroenterol* (2014) 20(36):12753–66. doi: 10.3748/wjg.v20.i36.12753

34. Junaid M, Linn AK, Javadi MB, Al-Gubare S, Ali N, Katzenmeier G. Neutrophil-Activating Protein of Helicobacter Pylori Promotes Th1 Immune Response. *Toxicon* (2016) 116:27–35. doi: 10.1016/j.toxicon.2016.04.037

35. Guo Y, Feinberg H, Conroy E, Mitchell DA, Alvarez R, Bluxt O, et al. Structural Basis for Distinct Ligand-Binding and Targeting Properties of the Receptors DC-SIGN and DC-SIGNR. *Nat Struct Mol Biol* (2011) 18:591–8. doi: 10.1038/nsmb784

36. D’Elia MM, Amedei A, Cappon A, Del Prete G, de Bernardi M. The Neutrophil-Activating Protein of Helicobacter Pylori (HP-NAP) as an Immune Modulating Agent. *FEMS Immunol Med Microbiol* (2007) 50(2):157–64. doi: 10.1111/j.1574-695X.2007.00258.x

37. Amedei A, Cappon A, Codofo G, Cabrelle A, Polenghi A, Benagiano M, et al. The Neutrophil-Activating Protein of Helicobacter Pylori Promotes Th1 Immune Responses. *J Clin Invest* (2006) 116(4):1092–1101. doi: 10.1172/jci27177

38. Benkendorfer J, Barone A, Johannson MM, Tenenberg S. Helicobacter Pylori SAKA Binding Gangliosides of Human Stomach. *Vireulence* (2018) 9(1):738–51. doi: 10.1080/21505594.2018.1440171
96. Cover TL, Vaughn SG, Cao P, Blaser MJ. Potentiation of Helicobacter Pylori Vacculating Toxin Activity by Nicotine and Other Weak Bases. J Infect Dis (1995) 172(1):37–8. doi: 10.1093/med.165.5.1073

97. Chevalier C, Thiberge JM, Ferrero RL, Labigne A. Essential Role of Helicobacter Pylori Gamma-Glutamyltranspeptidase for the Colonization of the Gastric Mucosa of Mice. Mol Microbiol (1999) 31(5):1359–72. doi: 10.1046/j.1365-2958.1999.01271.x

98. Yokoyama K, Higashi H, Ishikawa S, Fujii Y, Kondo S, Kato H, et al. Helicobacter Pylori Outer Membrane Vesicles Protect the Pathogen in a Dependent Vacculation in the Gastric Epithelial Cells. Proc Natl Acad Sci USA (2005) 102(27):9661–6. doi: 10.1073/pnas.0505292102

99. Ling SSM, Khoo LHB, Hwang J-A, Yeo Y-K, Ho B. Inseparable Role of Helicobacter Pylori γ-glutamyl Transpeptidase in VacA-Dependent Vacculation in the Gastric Epithelial Cells. PLoS One (2015) 10(6):e0131460. doi: 10.1371/journal.pone.0131460

100. Zhang L, Hu W, Cho CH, Chan FK, Yu J, Fitzgerald JR, et al. Reduced Deposition and Reactivity With Homologous Antibodies. J Pathol (2019) 15(11):e1000847–e. doi: 10.1111/jpath.1000847

101. Lekmeechai S, Su Y-C, Brant M, Alvarado-Kristensson M, Vallström A, Obi S, et al. Helicobacter Pylori EXPRESS a Complex Surface Carbohydrate, Lewis X. Infect Agents Med (2014) 5:33. doi: 10.1186/s11705-014-0057-7

102. Xue J, Li L, Li F, Li N, Li T, Li C. Expression of Lewis (B) Blood Group Antigens Interferes With Oral Diengnostic Therapy Among Women With Adenomyosis. J Reprod Immunol (2020) 137:103079. doi: 10.1016/j.jri.2019.103079

103. de Mattos LC. Structural Diversity and Biological Importance of ABO, Lewis Antigen Glycosylation of Helicobacter Pylori LPS During Persistent Infection. Proc Natl Acad Sci USA (2006) 103(8):2863–8. doi: 10.1073/pnas.0511119103

104. Moran A. The Role of Lipopolysaccharide in Helicobacter Pylori Pathogenesis. Alimentary Pharmacol Ther (1996) 10(Sup1):39–50. doi: 10.1046/j.1365-2014.1996.10.s1.39.x

105. Nilsson C, Skoglund A, Moran AP, Annuk H, Engstrand L, Normark S. An Enzymatic Ruler Modulates Lewis Antigen Glycosylation of Helicobacter Pylori LPS. Infect Immun (2016) 84(7):2863–8. doi: 10.1128/iai.00532-16

106. Muotuula A, Helander IM, Pyhälä L, Kosunen TU, Moran AP. Low Biological Activity of Helicobacter Pylori Lipopolysaccharide. Infect Immun (1992) 60(4):1714–6. doi: 10.1128/iai.60.4.1714-1716.1992

107. Yamaji Y, Mitsushima T, Ikuma H, Okamoto M, Yoshida H, Kawabe T, et al. Helicobacter Pylori Lipopolysaccharide and Lipid A. Int J Med Microbiol (2007) 297(5):307–19. doi: 10.1016/j.ijmm.2007.03.008

108. Shimoyama A, Saei K, Tanimura N, Tsutsui H, Miyake K, Suda Y, et al. Chemical Synthesis of Helicobacter Pylori Lipopolysaccharide Partial Structures and Their Selective Proinflammatory Responses. Chem A Eur J (2011) 17(51):14464–74. doi: 10.1002/chem.201003581

109. Fujimoto Y, Shimoyama A, Suda Y, Fukase K. Synthesis and Immunomodulatory Activities of Helicobacter Pylori Lipopolysaccharide Terminus of Lipopolysaccharide Including Lipid A. Carbohydr Res (2012) 356:37–43. doi: 10.1016/j.carres.2012.03.013

110. Obonyo M, Sabet M, Cole SP, Ebmeyer J, Uematsu S, Akira S, et al. Deficiencies of McIoyid Differentiation Factor 88, Toll-Like Receptor 2 (TLR2), or TLR4 Produce Specific Defects in Macrophage Cytokine Secretion Induced by Helicobacter Pylori. Infect Immun (2007) 75(5):2408–14. doi: 10.1128/IAI.01794-06

111. Cullen TW, Giles DK, Wolf LN, Ecobichon C, Boneca IG, Trent MS. Helicobacter Pylori Versus the Host: Remodeling of the Bacterial Outer Membrane Is Required for Survival in the Gastric Mucosa. PLoS Pathog (2011) 7(11):e1002454. doi: 10.1371/journal.ppat.1002454

112. Liu A-N, Teng K-W, Chew Y, Wang P-C, Nguyen TTH, Kao M-C. The Effects of HP0044 and HP1275 Knockout Mutations on the Structure and Function of Lipopolysaccharide in Helicobacter Pylori Strain 26695. Biomolecules (2022) 10(1):145. doi: 10.3390/biomolecules10010145

113. Moran AP, Knirel YA, Chenenko SV, Widmalm G, Hynes SO, Jansson JL. Phenotypic Variation in Molecular Mimicry Between Helicobacter Pylori Lipopolysaccharides and Human Gastric Epithelial Cell Surface Glycoconjugates. Acta Biochim Biophys Sin (2014) 46(5):195–204. doi: 10.1189/abbs.2014.0212

114. Monteiro MA, Appelmelk BJ, Rasko DA, Moran AP, Hynes SO, MacLean LL, et al. Lipopolysaccharide Structures of Helicobacter Pylori Genomic Strains 26695 and J99. Model Mouse H. Pylori Sydney Strain, H. Pylori P466 Carrying Sialyl Lewis X, and H. Pylori U915 Expressing Lewis B Classification of Helicobacter Pylori Lipopolysaccharides Into Glycofamilies. Front Immunol (2020) 11:610. doi: 10.3389/fimmu.2020.00610

115. Lozniewski A, Haristoy X, Rasko DA, Hatier R, Ple http://www. frontiersin.org
Internalization by Gastric Epithelial Cells. *Infect Immun* (2003) 71(5):2902–6. doi: 10.1128/iai.71.5.2902-2906.2003

113. Gonciarz W, Walencka M, Moran AP, Hinc K, Obuchowski M, Chmiel flat Facilitate Gastric Tissue Colonization and the Maintenance of Infection. *J Biomed Sci* (2019) 26 (1):23. doi: 10.1186/s12929-019-0515-z

112. Boren T, Falk P, Roth KA, Larson G, Normark S. Attachment of Helicobacter Pylori to Human Gastric Epithelium Mediated by Blood Group Antigens. *Science* (1993) 262(5141):1892. doi: 10.1126/science.8018146

111. Iver D, Arnegård B, Ogren J, Frick IM, Kersulyte D, Incecik ET, et al. Helicobacter Pylori Adhesin Binding Fucosylated Histo-blood Group Antigens Revealed by Retagging. *Science* (1998) 279(5349):373–7. doi: 10.1126/science.279.5349.373

110. Moonens K, Gideonsson P, Subedi S, Bugaytsova J, Romaõ E, Mendez M, et al. Structural Insights Into Polymorphic ABO Glycan Binding by Helicobacter Pylori. *Cell Host Microbe* (2016) 19(1):55–66. doi: 10.1016/j.chom.2015.12.004

109. Matteo MJ, Armitano RI, Romeo M, Wonaga A, Olmos M, Catalano M. Upregulation of MUC5AC Production and Deposition of LEWIS Determinants by HELICOBACTER PYLORI. *J Biomed Sci* (2019) 26 (1):23. doi: 10.1186/s12929-019-0515-z

108. Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, et al. Helicobacter Pylori Adhesin Binding Fucosylated Histo-blood Group Antigens Revealed by Retagging. *Science* (1998) 279(5349):373–7. doi: 10.1126/science.279.5349.373

107. Moonens K, Gideonsson P, Subedi S, Bugaytsova J, Romaõ E, Mendez M, et al. Structural Insights Into Polymorphic ABO Glycan Binding by Helicobacter Pylori. *Cell Host Microbe* (2016) 19(1):55–66. doi: 10.1016/j.chom.2015.12.004

106. Bäckström A, Lundberg C, Kersulyte D, Berg DE, Bore E, Hurtig M, Olfat FO, Forsberg L, Roche N, et al. Metastability of Helicobacter Pylori Bab Adhesin Genes and Dynamics in Population in This Journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction which does not comply with these terms.